Inclusion Criteria:

- 1. Generally healthy adults aged 18 years or older at the time of enrollment and with a
body mass index (BMI) of ≤30 kg/m2

- Completion of a prior COVID-19 primary vaccination course or booster (any
commercially available within the study country) at least 3 months prior to
enrollment OR recent clinically documented SARS-CoV-2 infection (by polymerase chain
reaction [PCR] or antibody test) in the past three months but not within one month
from enrollment.

- Willing to refrain from receiving an authorized COVID-19 booster dose until at least
90 days post IP administration.

- Female participants of child-bearing potential must have practiced adequate
contraception for 30 days before IP injection, have a negative pregnancy test on the
day of IP injection, and agree to continue adequate contraception until 180 days
after IP injection. (Please refer to Section 10.44 for the definition of
childbearing potential and adequate contraception).

- Male participants must agree to continue adequate contraception until 180 days after
IP injection.

- Able to consent to participate in the study and signed an Informed Consent Form
(ICF).

- Able and willing to complete all the scheduled study procedures during the whole
study period (approximately 6.5 months).

- Generally, in good health, as determined by a review of medical history and a
physical examination within 14 days prior to IP injection.

Exclusion Criteria:

- 1. History of anaphylaxis to key ingredients within the vaccine. 2. History of
seizure disorder, encephalopathy, or psychosis. 3. Female participant is pregnant
(positive urine pregnancy test), lactating, or plans to become pregnant during the
180 days of enrollment. 4. Positive test result for human immunodeficiency virus
(HIV) or hepatitis B and C at Screening (test to be performed at the discretion of
the investigator based on medical history or physical examination). 5. Positive
result of lateral flow test for SARS-COV-2 on Day 0. 6. Laboratory (hematological
and biochemistry) examination that is out of normal range or greater than a Grade 2
abnormality. Grade 1 abnormalities will not be exclusionary if considered not
clinically significant by the investigator. Laboratory tests include: complete blood
count (CBC), prothrombin time (PT), partial thromboplastin time (PTT), alanine
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALP), total bilirubin (T Bil), creatinine (CR), lipase, and blood glucose at
screening. 7. Transient mild laboratory abnormalities may be rescreened once, and
the participant will be excluded if the laboratory repeat test is abnormal as per
local laboratory normal values and the investigator's assessment. 8. Presents with
any acute febrile disease (oral temperature ≥37.5°C [99.5oF]) or active infectious
disease within 48 hours prior to IP injection. 9. Unstable concomitant underlying
conditions. Note: Stable condition defined as: the participant is appropriately
managed on consistent disease management; for example, participants with
well-controlled hypertension, adult-onset diabetes, benign prostate hypertrophy, or
hypothyroid disease will be eligible for enrollment. The treatment regimen should be
stable for at least 3 months prior to entering the study. Once IP treatment has
started, the patient must be willing to maintain all aspects of the treatment
regimen and forgo any elective changes in medication or management. Emergency
changes in medication or management would be captured as an AE. 10. History of
Guillain-Barre Syndrome or degenerative neurological disorders; a history of
autoimmune, inflammatory disease or potential immune-mediated diseases (pIMD), or
any condition that may put the participant at increased risk of safety events. 11.
History of serious cardiovascular diseases, such as arrhythmia, conduction block,
history of myocardial infarction, and severe hypertension not controlled with
medication. 12. History of immunodeficiency, asplenia, or functional asplenia. 13.
History of platelet disorder or other bleeding disorder that may cause
contraindication for IM injection. 14. Heavy smoker (>10 cigarettes per day), vaper
(>1 mL of e-liquid per day), or cannabis user ([near] daily use). Smokers have to
agree to use the same cigarette brand throughout the study.

15. History or diagnosis of coagulopathies. 16. Prior receipt of immunosuppressive
medication, cytotoxic therapy, or systemic corticosteroids within 6 months before
Day 0. 17. Recent receipt of blood products within 4 months before Day 0. 18.
Administration of other investigational drugs within 3 months before Day 0 or
planned use during the study period. 19. Currently has or a history of any condition
that, in the opinion of the investigator, may interfere with the participant's
compliance, evaluation of study objectives, or informed consent process (i.e.,
medical, psychological, social, or other conditions).